Hepatotoxicity and TNF Inhibitors

Save

Hepatic enzyme elevations with TNF inhibitor use is not uncommon.

Lancet: Increase Serious Infection Risk with Biologics

Save

RA Compliance Undermines Treatment Success

Save

Researchers at MD Anderson Cancer Center in Houston prospectively studied 107 RA patients with regard to oral medication (DMARDs, steroids) adherence. They report that adherence was low, ranging from 58-71% overall.

Zoster Risk is Similar Among Different MOA Biologics

Save

The risk of new H zoster infection was studied among nearly 30,000 new biologic starts and compared rates seen with abatacept, adalimumab, rituximab, infliximab, etanercept, tocilizumab, certolizumab or golimumab initiation.

The Risk of Listeriosis in RA

Save

In the mid-1990s, our Rheumatology Division at the University of Texas Southwestern Medical School became involved with an early trial of a brand new TNF inhibitor.

Is There a Standout When Comparing Novel Therapies?

Save

Randomized clinical trials are needed to show efficacy and safety, and are needed to back up the claims and indications for a particular drug. The issue of treatment choice has become challenging, especially when choosing to start or augment therapy.

FDA Outlines its Guidance for Biosimilars

Save

The FDA has released its guidance document on biosimilar development, stating that this represents its current thinking and may not be the final document. The document was published last week and will be instrumental in the development of biosimilar products in this country. In the

Drug-Induced Lupus is Rare with TNF inhibitor Therapy

Save

Real World Biologic Success in Systemic JIA

Save

A retrospective review of 77 SoJIA patients revealed that 50-70% achieved inactive disease or remission when treated with IL-1 inhibitors (anakinra, canakinumab). Good responses were seen with tocilizumab or abatacept, but only 8% responded to etanercept.

DRESS Trial Shows TNFi Dose Reduction is Possible - Without Major Flares

Save

Can TNF inhibitor therapy be withdrawn in RA patients who are in remission?  The DRESS trial reports the results of randomized trial of 180 RA patients taking either etanercept or adalimumab. Patients were randomly assigned to either usual care (no dose reduction) or a stepwise increase

HLA-DRB1 Alleles Augment RA Severity and TNF Inhibitor Responses

Save

The HLA-DRB1 haplotype is a known risk factor for RA.

The Science and Faith of Herpes Zoster Management

Save